150 related articles for article (PubMed ID: 10837943)
1. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials.
Roach M; Lu J; Pilepich MV; Asbell SO; Mohiuddin M; Terry R; Grignon D
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):609-15. PubMed ID: 10837943
[TBL] [Abstract][Full Text] [Related]
2. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials.
Roach M 3RD ; Lu J; Pilepich MV; Asbell SO; Mohiuddin M; Terry R; Grignon D; Lawton C; Shipley W; Cox J
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):617-27. PubMed ID: 10837944
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival after radiotherapy alone: radiation therapy oncology group prostate cancer trials.
Roach M; Lu J; Pilepich MV; Asbell SO; Mohiuddin M; Terry R; Grignon D
J Urol; 1999 Mar; 161(3):864-8. PubMed ID: 10022702
[TBL] [Abstract][Full Text] [Related]
4. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
5. The 1989 patterns of care study for prostate cancer: five-year outcomes.
Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
[TBL] [Abstract][Full Text] [Related]
6. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
Roach M; Lu J; Pilepich MV; Asbell SO; Mohiuddin M; Grignon D
J Urol; 2003 Jan; 169(1):245-50. PubMed ID: 12478146
[TBL] [Abstract][Full Text] [Related]
7. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
[TBL] [Abstract][Full Text] [Related]
9. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
[TBL] [Abstract][Full Text] [Related]
10. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
11. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
12. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
[TBL] [Abstract][Full Text] [Related]
13. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.
Horwitz EM; Hanlon AL; Pinover WH; Anderson PR; Hanks GE
Cancer; 2001 Sep; 92(5):1281-7. PubMed ID: 11571744
[TBL] [Abstract][Full Text] [Related]
14. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
Roach M; Weinberg V; Sandler H; Thompson I
Cancer; 2007 Jan; 109(2):213-20. PubMed ID: 17167758
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.
Pollack A; Zagars GK; Kopplin S
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):13-20. PubMed ID: 7536720
[TBL] [Abstract][Full Text] [Related]
17. Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980-1998).
Magrini SM; Bertoni F; Vavassori V; Villa S; Cagna E; Maranzano E; Pertici M; Pradella R; Spediacci MA; Chiavacci A; Ambrosi E; Livi L; Magli A; Bellavita R; Bossi A; Biti G
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1310-9. PubMed ID: 11955744
[TBL] [Abstract][Full Text] [Related]
18. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials.
Valicenti R; Lu J; Pilepich M; Asbell S; Grignon D
J Clin Oncol; 2000 Jul; 18(14):2740-6. PubMed ID: 10894874
[TBL] [Abstract][Full Text] [Related]
19. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
20. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer.
Rusthoven CG; Waxweiler TV; DeWitt PE; Flaig TW; Raben D; Kavanagh BD
Urol Oncol; 2015 Feb; 33(2):71.e11-9. PubMed ID: 25151595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
